article thumbnail

CAMP4’s funding influx paves the way for tapping regulatory RNA to treat urea cycle disorders

Pharmaceutical Technology

Last week, CAMP4 Therapeutics announced the close of a $100 million Series B round , which will be used to advance their regulatory RNA (regRNA)-focused programs. In preparation for this, drug manufacturing will begin later this year and will be outsourced to external contract manufacturing organisations (CMOs).

RNA 245
article thumbnail

mRNA: A New Era in Biopharmaceutical Contract Manufacturing Market

Roots Analysis

Given such technical and operational challenges associated with the production of RNA-based products, innovators in the biopharmaceutical industry are increasingly relying on the contract manufacturing service providers to cater to the urgent global demand.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Growing Demand for Oligonucleotides Proposes Shedload of Opportunities for Contract Manufacturers

Roots Analysis

In the 20 th century, major research went into discovery of a therapeutic class with the primary purpose of interfering with the RNA expression linked to disease causing proteins, nowadays classified as oligonucleotides. These contract service providers are actively entering into strategic collaborations to augment their existing portfolios.

article thumbnail

Aurora Biosynthetics launches to boost RNA therapeutics manufacturing in Asia-Pacific

BioPharma Reporter

The new company focuses on producing components needed to manufacture RNA-based therapies for which there is increasing demand.

RNA 59
article thumbnail

ReciBioPharm’s Edita Botonjic-Sehic on analytics, AI, and continuous RNA manufacturing

BioPharma Reporter

RNA therapeutics have emerged as a transformative approach to treating many conditions, but the industry still typically relies on inefficient batch manufacturing methods.

RNA 52
article thumbnail

BioSig abandons COVID-19 drug trial on safety concerns

pharmaphorum

Things were looking promising for the project as recently as last month, when BioSig said it was doubling the size of the study from 40 to 80 patients and hiring a contract manufacturer to produce supplies for a phase 3 trials programme.

article thumbnail

Novo Nordisk’s gene silencing alliance with Dicerna bears first fruit

pharmaphorum

million – including $175 million upfront and an equity investment of $50 million – to find multiple RNA interference (RNAi) candidates for diseases like non-alcoholic steatohepatitis (NASH) and type 2 diabetes. Danish drugmaker Novo Nordisk signed a deal with the US biotech in 2019 valued at up to $675.5